Business Ethics

M-23381 Profit Over

Saadia Syed Ali
Patients
Big Pharma's Exploitation
of Health and the Urgent
Call for Accountability and
Ethical Reform

Group Members
SYED FARZAN NADIR 20221-31721
ZUNAIRA NARMEEN 20211-30413
Table of Contents
Industry Background ..................................................................................................................................... 2
History ...................................................................................................................................................... 2
Global Pharma Manufacturing Market ..................................................................................................... 2
Pharmaceutical Regulations ...................................................................................................................... 2
Major Companies ...................................................................................................................................... 4
Medical research is conducted in developing countries to avoid ethics legislation ...................................... 7
Systemic Ethical Violations at IHU Méditerranée Infection, France ........................................................... 8
China’s Pharma Bribery Scandal and Ethical Failures in the Global Drug Market ...................................... 9
Clinical Trial Scandal At VS Hospital: Patients Exploited, Crores Diverted In Pharma-Hospital Nexus.. 11
Unethical Pricing: Why Do Medicines Cost So Much?.............................................................................. 13
Lies in Drug Research: Hiding the Truth to Sell Pills ................................................................................ 14
Social Harm: Pills That Kill Trust .............................................................................................................. 15
Future Risks: Robots and Rumors .............................................................................................................. 17
Fixing the System: Rules to Save Lives...................................................................................................... 19
Conclusion: Health Over Profit................................................................................................................... 21
References ................................................................................................................................................... 22
Industry Background
History
The pharmaceutical industry has its roots in the apothecaries and pharmacies of medieval times,
where traditional remedies were prepared based on folk knowledge. It began to formalize in the
19th century, driven by scientific and industrial advancements. German company Merck,
founded as a pharmacy in 1668, transitioned to industrial medicine production in 1827, while
Beecham, a forerunner of GlaxoSmithKline, built the world’s first medicine factory in 1859. In
the United States, firms like Pfizer and Eli Lilly emerged in the mid-1800s, expanding through
innovations in drug manufacturing and rising demands during wars.
Switzerland’s pharmaceutical industry grew from its dye trade, with companies like Roche and
CIBA-Geigy entering medicine production in the late 19th century. Bayer’s introduction of
aspirin around 1900 became a landmark in pharmaceutical history. The 20th century brought
critical breakthroughs, such as insulin for diabetes and penicillin during World War II, which
transformed modern medicine. The post-war period saw national healthcare systems, regulatory
reforms, and a surge in pharmaceutical research, though public concerns about ethics and drug
safety grew, particularly after the Thalidomide incident in 1961.
The industry’s ‘golden age’ in the latter half of the 20th century introduced innovations like the
contraceptive pill, Valium, and blockbuster drugs such as Tagamet. Later, biotechnology and
genetic research opened new frontiers, leading to targeted cancer therapies and gene treatments.
While pharmaceutical progress continues, challenges like drug affordability, antimicrobial
resistance, and public trust remain central issues for the industry today.

Global Pharma Manufacturing Market

The pharmaceutical industry has experienced significant transformation with the integration of
advanced technologies. The adoption of Artificial Intelligence (AI) has notably improved
manufacturing efficiency by reducing production costs and time, while enhancing drug
development processes. Growing investment in pharmaceutical research and technology has
further contributed to market expansion. In 2020, the global pharmaceutical manufacturing
market was valued at USD 405.52 billion, with projections indicating steady growth at a high
compound annual growth rate in the coming years. Additionally, the industry has seen a surge in
mergers and acquisitions, as established companies consolidate their market presence and
navigate stringent regulatory frameworks that have placed caps on drug pricing. This highly
competitive environment has accelerated innovation and production within the pharmaceutical
manufacturing sector.
Pharmaceutical Regulations
The evolution of pharmaceutical regulations has been pivotal in ensuring the safety, efficacy, and
quality of drugs available to consumers. In the early stages of pharmaceutical development, the
focus was primarily on innovation and entrepreneurship, with minimal oversight. However, as
the industry matured, the necessity for stringent regulatory frameworks became evident to
protect public health.
One of the earliest significant regulatory milestones in the United States was the Biologics
Control Act of 1902, enacted after contaminated vaccines led to fatalities. This act mandated
premarket approval for biological drugs and the facilities producing them. Subsequently, the
Pure Food and Drug Act of 1906 prohibited the interstate commerce of adulterated and
misbranded drugs, laying the foundation for federal drug regulation.
The Federal Food, Drug, and Cosmetic Act of 1938 further expanded regulatory oversight by
requiring manufacturers to provide evidence of drug safety before marketing. This act also
authorized the Food and Drug Administration (FDA) to conduct factory inspections. The
thalidomide tragedy in the late 1950s, where a drug caused severe birth defects, underscored the
importance of rigorous drug evaluation. In response, the Kefauver-Harris Amendments of 1962
mandated proof of drug efficacy and informed consent from clinical trial participants.
Today, the FDA's role encompasses the entire lifecycle of a drug, from preclinical research
through post-market surveillance. The agency ensures that drugs meet established standards for
safety and effectiveness, and it monitors adverse events once products are on the market.
Additionally, the FDA provides guidance to pharmaceutical companies during drug
development, helping to streamline the approval process while maintaining rigorous standards.
Globally, other countries have established their own regulatory bodies, such as the European
Medicines Agency (EMA) in the European Union and the Medicines and Healthcare products
Regulatory Agency (MHRA) in the United Kingdom. These agencies collaborate with the FDA
and each other to harmonize regulatory standards, facilitating the global distribution of safe and
effective [Link] progression from minimal oversight to comprehensive regulatory
frameworks has been instrumental in safeguarding public health. Regulatory agencies like the
FDA play a crucial role in ensuring that pharmaceutical innovations are both safe and effective,
reflecting the industry's commitment to rigorous standards and continuous improvement.
Major Companies
 Pfizer Inc.
Founded in 1849, Pfizer is an American multinational pharmaceutical and biotechnology
corporation. It gained global recognition for developing one of the first approved COVID-19
vaccines in partnership with BioNTech. The company’s portfolio includes medicines across
oncology, cardiology, immunology, and vaccines.
 Johnson & Johnson
Headquartered in the United States, Johnson & Johnson operates across three primary
sectors: pharmaceuticals, medical devices, and consumer health products. It is known for
prescription medications such as Remicade and Stelara, along with everyday healthcare
products like Band-Aid and Tylenol.
 Roche Holding AG
Based in Switzerland, Roche is a global leader in oncology, immunology, and diagnostics.
The company’s best-selling cancer drugs include Avastin, Herceptin, and Rituxan. Roche is
also recognized for its significant contributions to diagnostics and personalized medicine.
 Novartis International AG
Another Swiss pharmaceutical giant, Novartis focuses on innovative medicines, generics, and
biosimilars. The company has a robust oncology division and is known for blockbuster drugs
like Cosentyx (for psoriasis) and Entresto (for heart failure).
 Merck & Co., Inc.
Known as MSD outside the United States and Canada, Merck is an American pharmaceutical
company renowned for its cancer immunotherapy drug Keytruda and vaccines like Gardasil.
The company has a long history of breakthroughs in infectious diseases and oncology.
 Sanofi S.A.
A French multinational pharmaceutical company, Sanofi specializes in prescription
medicines, vaccines, and consumer healthcare products. It is known for insulin products like
Lantus and its strong presence in the global vaccine market through Sanofi Pasteur.
 GlaxoSmithKline (GSK)
Based in the United Kingdom, GSK focuses on pharmaceuticals, vaccines, and consumer
healthcare. The company is notable for respiratory medicines, vaccines for meningitis and
hepatitis, and consumer brands like Panadol and Sensodyne.
 AbbVie Inc.
Spun off from Abbott Laboratories in 2013, AbbVie is an American biopharmaceutical
company known for its top-selling immunology drug Humira. The company has expanded its
portfolio through acquisitions, notably acquiring Allergan, the maker of Botox.
 AstraZeneca plc
A British-Swedish multinational, AstraZeneca gained significant attention during the
COVID-19 pandemic for developing one of the widely distributed vaccines. Its therapeutic
areas include oncology, cardiovascular, respiratory, and immunology.
 Eli Lilly and Company
Headquartered in the United States, Eli Lilly is recognized for its diabetes treatments,
including Humalog and Trulicity, and psychiatric medications such as Prozac. The company
is actively expanding its oncology and immunology pipelines.
 CSL Limited
CSL is an Australian multinational specialty biotechnology company and one of the world’s
largest producers of plasma-derived therapies. The company focuses on immunoglobulins,
coagulation therapies, and vaccines. CSL's influenza vaccine division, Seqirus, is one of the
largest influenza vaccine providers globally. The company has a strong reputation for
innovation in treating rare and serious diseases.
 Daiichi Sankyo Co., Ltd.
Headquartered in Japan, Daiichi Sankyo is a global pharmaceutical company specializing in
cardiovascular medicine and oncology. Its most notable product is Enhertu, a leading breast
cancer therapy developed in collaboration with AstraZeneca. The company has expanded its
oncology portfolio aggressively in recent years and is known for research-driven
pharmaceutical advancements.
Medical research is conducted in developing countries to avoid
ethics legislation

The pharmaceutical industry has historically faced criticism for unethical practices, particularly
concerning clinical trials conducted in low and middle-income countries. One such alarming
practice is 'ethics dumping' — where research deemed unethical or heavily regulated in a
pharmaceutical company's home country is instead carried out in countries with weaker ethical
oversight.

A particularly notorious example is the case of cervical cancer screening trials conducted in
India between 1995 and 2015, funded in part by the US National Cancer Institute and the Bill
and Melinda Gates Foundation. The trials involved over 374,000 women, with 141,000 placed
in a control group with no screening at all. This led to 254 preventable deaths from cervical
cancer, as the control group received no intervention despite the known risks — a design that
would have been ethically impermissible in the United States or Europe.

Moreover, the case of US pharmaceutical firm Biogen Idec enrolling impoverished women
from India’s Dalit caste into heart-failure-prevention drug trials without proper informed consent
highlights another dimension of ethics dumping. Participants, many unable to read or understand
the documents presented to them, were subjected to experimental treatments without fully
grasping the risks involved. Tragically, some participants, like Chandrakala Bai, died shortly
after being administered trial medications.

These instances underline the inequitable power dynamics between research organisations
and vulnerable populations in developing countries. Often, participants lack the legal
recourse, advocacy structures, or economic means to seek justice for harm caused during
unethical trials. This exploitation persists due to inadequate local regulations and monitoring
mechanisms.

To combat this, initiatives like the TRUST Project — a collaborative effort between the
European Commission and indigenous groups like South Africa’s San people — have
introduced codes of ethical guidelines. These frameworks seek to protect vulnerable
communities and demand that research upholds universal human rights, irrespective of
geography.

Incorporating ethically responsible research practices is no longer optional but a critical

requirement for the pharmaceutical industry. Multinational companies must be held accountable
not only within their home countries but also abroad, ensuring transparency, informed consent,
and equal treatment of all trial participants.
Systemic Ethical Violations at IHU Méditerranée Infection, France

The IHU Méditerranée Infection institute in Marseille, under the leadership of Professor Didier
Raoult, has been at the center of extensive ethical controversies. Investigations have uncovered a
pattern of unethical research practices spanning over three decades, involving vulnerable
populations and lacking proper oversight.
Unapproved Clinical Trials on Vulnerable Populations
One of the most alarming instances involved the "Mycobac" protocol, an unauthorized clinical
trial targeting tuberculosis patients. This study included minors, non-French speakers, and
homeless individuals—groups particularly susceptible to exploitation. The trial proceeded
without appropriate ethical approvals, and participants were subjected to treatments not aligned
with international standards, leading to serious adverse effects. The French General Inspectorate
of Social Affairs (IGAS) reported that these practices likely constitute criminal offenses due to
the absence of informed consent and the inclusion of vulnerable individuals without proper
safeguards.
Ethical Oversight Failures in International Research
Further scrutiny revealed that IHU researchers conducted studies in African countries, collecting
biological samples from malnourished children without obtaining ethical approvals from local
authorities. Two such studies were retracted by Scientific Reports after it was found that the
same ethics approval number was reused across multiple studies, regardless of differing research
questions and participant populations. This practice violates ethical standards and undermines the
autonomy and rights of research subjects.
Systemic Misuse of Ethics Approvals
An extensive review identified ethical concerns in 456 studies associated with the IHU, with 248
of them citing the same ethics approval number despite variations in study design and participant
demographics. This pattern indicates a systemic failure to obtain proper ethical clearances,
raising serious questions about the institute's research integrity. The
Consequences and Institutional Response
In response to these violations, French health authorities imposed restrictions on the IHU's
research activities and initiated legal proceedings. Several studies have been retracted, and
investigations are ongoing to address the breadth of ethical misconduct.
China’s Pharma Bribery Scandal and Ethical Failures in the Global
Drug Market

In 2013, China launched one of its most significant anti-corruption investigations into the
pharmaceutical sector, uncovering widespread unethical practices by several global drug
manufacturers operating within its borders. The scandal began with allegations against British
pharmaceutical giant GlaxoSmithKline (GSK) and later implicated numerous other
multinationals, including Sanofi (France), Bayer (Germany), Eli Lilly (USA), Novo Nordisk
(Denmark), H. Lundbeck (Denmark), AstraZeneca (UK-Sweden), and UCB (Belgium).

Key Ethical Violations:

 Bribery and Corruption:
GSK executives allegedly used travel agencies to covertly funnel illegal payments to Chinese
doctors and government officials. These bribes were intended to secure favorable treatment
for the company’s drugs — including increased prescriptions and approval for use in
hospitals.
 Inappropriate Influence on Medical Decision-Making:
By offering financial incentives to healthcare professionals, these companies directly
undermined the autonomy of clinical decisions, compromising patient care in favor of
corporate profits.
 Corporate Misgovernance:
Although GSK’s global leadership denied prior knowledge of the misconduct, the case raised
serious concerns about corporate responsibility and accountability in multinational
operations. With over 100,000 employees worldwide, maintaining ethical oversight becomes
both complex and essential in a globalized pharmaceutical market.
 Regulatory Disparities and Exploitation of Weaker Systems:
While developed countries had long implemented detailed codes of conduct limiting
interactions between doctors and pharma companies, emerging markets like China were
comparatively under-regulated. This regulatory gap enabled unethical marketing practices,
such as unchecked promotions, financial incentives, and unauthorized sales strategies.

Consequences and Industry-Wide Implication

The GlaxoSmithKline scandal resulted in a historic outcome, as the company was fined nearly
US$490 million, marking the largest corporate penalty ever imposed in China at the time.
Beyond the immediate legal repercussions, the incident exposed deeper, systemic issues within
global pharmaceutical governance. It illustrated how multinational corporations could exploit
regulatory gaps and ethical loopholes in less strictly governed economies to advance their
commercial interests at the expense of public welfare and fair medical practices. The case
emphasized the urgent need for the global harmonization of ethical standards in pharmaceutical
operations. It highlighted the importance of implementing robust, enforceable oversight
mechanisms and comprehensive corporate integrity agreements to ensure consistent ethical
conduct across all markets, regardless of local regulatory disparities.
Clinical Trial Scandal At VS Hospital: Patients Exploited, Crores
Diverted In Pharma-Hospital Nexus

Between 2021 and 2024, Ahmedabad’s VS Hospital became the epicenter of one of India’s most
alarming medical ethics scandals in recent years. What was presented as routine clinical drug
research turned out to be a calculated exploitation of vulnerable patients, systemic regulatory
loopholes, and unethical collaboration between pharmaceutical companies, hospital officials, and
private ethics committees.
According to investigations by Vibes of India and other media outlets, 58 clinical drug trials were
conducted at VS Hospital during this period. Under national norms, pharmaceutical firms are
required to pay 40% of the trial’s total cost as an establishment fee to the hospital. However,
hospital officials allegedly charged only 10% — allowing pharma companies to evade
substantial costs. The remaining 30% was reportedly pocketed by officials through kickbacks.
This arrangement was enabled after a 2019 restructuring, which resulted in VS Hospital being
removed from the jurisdiction of NHL Medical College’s ethics committee. This separation
allowed hospital management to obtain trial approvals from private ethics committees within a
50 km radius, bypassing the stricter SVP Hospital ethics committee nearby.
Further, allegations surfaced that some pharmaceutical companies bribed doctors, Medical
Education Trust (MET) officials, and agents to approve and facilitate these trials. The clinical
trials, conducted primarily on poor and unsuspecting patients, lacked proper ethical oversight,
informed consent, and regulatory compliance.
An ongoing investigation by the Ahmedabad Municipal Corporation (AMC) involved several
key figures, including Dr. Devang Rana (suspended clinical trial head) and Dr. Manish Patel
(retired superintendent). While these officials defended the legality of the trials, multiple
discrepancies, including missing documentation and conflicting approvals, were reported.

Ethical Implications

Violation of Patient Rights:

The patients’ right to informed consent — a cornerstone of medical ethics — was blatantly
disregarded. Vulnerable individuals were subjected to experimental drug testing without
adequate information or comprehension of associated risks.
Breach of Professional Integrity:
Doctors and hospital administrators, bound by ethical codes, compromised their professional
integrity for personal and financial gain. This eroded public trust in medical professionals and
healthcare institutions.
Corporate Irresponsibility:
Pharmaceutical companies, instead of upholding ethical standards, exploited loopholes and
vulnerable populations for cost savings and expedited drug testing. Their actions reflected a
disregard for human rights and ethical business practices.
Systemic Governance Failure:
The scandal exposed glaring weaknesses in regulatory oversight and policy enforcement in
India’s pharmaceutical and healthcare sectors. The failure to monitor, audit, and enforce ethical
compliance enabled unethical practices to flourish.
Global Ethical Concerns:
This case mirrors issues observed globally, where multinational pharma firms often exploit
weaker healthcare regulations in developing economies. It reinforces the need for globally
harmonized ethical standards, corporate integrity agreements, and enforceable oversight
mechanisms.
Unethical Pricing: Why Do Medicines Cost So Much?

Pharmaceutical companies often justify sky-high drug prices by pointing to the huge, non-
recoverable costs of R&D and clinical trials, but in practice many exploits monopoly power and
regulatory loopholes to charge what the market will bear knowing that patients have almost no
price sensitivity when it comes to life-saving medicines. Patents, including “evergreening”
strategies that make minor tweaks to extend exclusivity, keep generics off the market long after
initial approval, and few manufacturers are willing to take on the technical complexity and
expense of biosimilars once a biologic’s patent expires. Manufacturers further tighten supply by
limiting production capacity or withholding inventory strategically, then compound delays and
costs through lengthy regulatory reviews and cold-chain logistics requirements. Finally, global
price fragmentation allows companies to charge wealthy countries premium rates while offering
discounts elsewhere, effectively shuttling the burden of R&D recoupment onto every market.
Worse still, these practices often tip into outright prices gouging clear ethical red flags under any
business-ethics framework. In 2015, Turing Pharmaceuticals acquired Daraprim, a decades-old
AIDS drug, and overnight jacked its price from $13.50 to $750 per tablet, a 5,455 % increase
that forced hospitals and patients to choose between bankruptcy and untreated infection. Insulin
prices have similarly ballooned, rising roughly 1,000 % over twenty years, pushing diabetics to
ration doses or skip them entirely, with life-threatening consequences. From a deontological
standpoint, these tactics treat patients as mere revenue streams rather than individuals with an
inherent right to health, and a utilitarian analysis shows that the social costs—avoidable deaths,
soaring healthcare spending, and undermined public trust, weigh far more heavily than any extra
corporate profit.
To realign pricing with ethical responsibility, companies must be subject to transparent, value-
based pricing models that tie cost to demonstrated patient benefit and long-term outcomes
instead of market tolerance. Stricter antitrust enforcement should automatically scrutinize patent
extensions and pay-for-delay deals, while international cooperation can close loopholes that
allow price discrimination between countries. Only by placing patient welfare ahead of short-
term revenue goals can the industry maintain its social license to operate and ensure that life-
saving treatments remain accessible to those who need them most.
Case Key Issue Impact
Turing Pharmaceuticals 5,000% price hike on Patients rationed medicine;
Daraprim global outrage; $456 Mi FTC
Settlement.
Insulin Price Novo Nordisk, Eli Lilly 1 in 4 diabetics skips doses;
Gouging colluded on pricing lawsuits filed for "murder-by-
markup."
Lies in Drug Research: Hiding the Truth to Sell Pills

Pharmaceutical companies have often put profits ahead of patient safety by hiding or spinning
clinical data to speed up drug approvals, extend patents, and boost sales—actions that clearly
clash with basic business ethics like honesty, fairness, and respect for people. For example, some
firms only published positive results from antidepressant trials in teenagers while burying
evidence of increased suicidal thoughts, and they’ve paid writers to ghost-write glowing articles
under the names of respected doctors. The Vioxx case is perhaps the most infamous: internal
documents showed Merck knew about serious heart risks as early as 1999 but waited years to
warn doctors, which may have led to tens of thousands of extra heart attacks before the drug was
finally pulled in 2004. Likewise, GlaxoSmithKline admitted in 2012 that it hid safety data on
Paxil in children, despite a lack of benefit and clear risk resulting in a $3 billion settlement that
barely scratched the surface of its earnings from off-label marketing.
Such tactics don’t stop there. Companies recruit “key opinion leaders” to give paid talks and
write reviews that emphasize benefits and gloss over risks, eroding trust in medical advice. They
also exploit loopholes by running small “post-hoc” analyses to claim new uses for existing drugs
without solid evidence effectively turning one patent into many. Roche’s promotion of Tamiflu,
for instance, rested on trial data kept out of sight; only after public pressure did partial results
reveal that the drug wasn’t as effective at preventing serious flu complications as originally
claimed.
From an ethical standpoint, these deceptions break the unspoken promise between pharmacists’
doctors and patients. A deontologist would say it treats people as mere tools for profit rather than
as individuals with rights. A utilitarian would point out that—when you add up higher healthcare
costs, lose trust, and unnecessary suffering from the damage far outweighs any extra revenue.
And social-contract theory reminds us that drug makers get special patent rights only because
society trusts them to share both benefits and risks.
Regulators have tried to clamp down by requiring trial registration, public reporting on sites like
[Link], and independent monitoring boards, but enforcement is spotty, and penalties
are often too small to deter bad behavior. Real change will take stiffer fines that claw back illicit
gains, genuinely independent ethics committees with real power, and a corporate culture that
rewards transparency and quickly addresses mistakes. Only by aligning business goals with
patient well-being can the industry rebuild trust and keep innovating in ways that truly serve
public health.
Case Key Issue Impact
Merck’s Vioxx Hidden cardiovascular risks 60,000 deaths; $4.85B
settlement.
Pfizer’s Bextra Off-label promotion $2.3B fine; trust eroded in
pharma marketing.
Social Harm: Pills That Kill Trust

When pharmaceutical companies put profits ahead of honest communication about drug risks
and benefits, they do real harm by breaking the trust that patients, doctors, and society place in
them. Business ethics calls on firms to treat everyone shareholders, patients, healthcare workers,
regulators, and the public with respect and fairness, but time and again we’ve seen big
drugmakers choose money over transparency. Take the opioid crisis: Purdue Pharma marketed
OxyContin as a safe, non-addictive painkiller. Doctors prescribed it widely, and people became
addicted; internal memos later showed the company knew of the risks but kept quiet. That kind
of cover-up betrays patients’ right to make fully informed choices.
Hiding bad news doesn’t just hurt individuals, it shakes public confidence in medicine itself.
When word gets out that a company withheld safety data, doctors grow wary of prescribing new
treatments, regulators face angry backlash, and public-health campaigns like vaccination drives
run into more skepticism and resistance. From a practical standpoint, the lives lost, and illnesses
left untreated because people don’t trust their doctors or new drugs far outweigh any short-term
gains the drugmaker might have made.
There’s also the problem of ghost-written articles and paid “key opinion leaders.” When
respected physicians unknowingly lend their names to industry-funded papers or talks that spin
trial results, patients and other doctors can’t tell what’s genuine science and what’s marketing.
This misleads everyone and violates two basic ethical rules: don’t lie by omission, and respect
people’s right to clear, honest information.
Even the rules meant to keep drug research honest, like registering clinical trials in advance,
disclosing conflicts of interest, and reporting side effects, only work if companies follow them.
Too often, firms find loopholes by highlighting only favorable trial results or running tiny
subgroup analyses that can’t prove real benefit. They even tweak existing patents to block
competitors longer, protecting profits at the expense of patient access.
Fixing this means more than slapping big fines on companies. It calls for a culture change where
ethics really matter. Drugmakers should set up independent ethics boards that can stop
questionable studies or marketing campaigns before they go live. They should share easy-to-read
summaries of all trial results, good and bad, and create public dashboards where anyone can see
real-time safety data. Incentive systems need to reward executives for improving patient
outcomes, not just hitting sales targets.
The payoff is worth it. Companies known for integrity build stronger relationships with
regulators, earn more trust from doctors, and win lasting loyalty from patients. In a world where
information travels fast and everyone can check the facts, the only sustainable path forward is
one where honesty and social responsibility lead, not lag, behind innovation.
Case Key Issue Impact
Purdue Pharma OxyContin misinformation 500,000+ deaths; bankruptcy;
$8.3B settlement.
COVID Vaccine Hoarding Rich vs. poor nation Prolonged pandemic; distrust in
disparities global health systems.
Future Risks: Robots and Rumors

As pharmaceutical companies bring in advanced automation, from robots that mix new
compounds to AI systems that design trials and monitor patients in real time, they face a fresh set
of ethical challenges that go beyond efficiency or speed. First, when opaque algorithms guide
everything from dosage recommendations to patient selection, there’s a real danger of bias or
mistakes slipping through. For instance, an AI model trained mostly on Western participants
might suggest doses that are unsafe or ineffective for people in Asia, Africa, or Latin America.
That kind of one-size-fits-all approach treats patients like data points rather than individuals
whose unique needs deserve respect.
On the marketing side, automated bots and personalized ad platforms can spread rumors just as
fast as facts. A single unverified claim, that a new antiviral is deadly, say, or that a specialty drug
is a miracle cure, can go viral on social media long before regulators or the company can correct
it. When false stories take off, people panic, demand unnecessary treatment, or lose faith in
legitimate breakthroughs, and the harm to public health easily outweighs any business benefit.
Outsourcing adds another layer of complexity. Many drugmakers rely on contract research firms
or “robotic pharmacy” services to handle data monitoring, report side effects, or even manage
parts of manufacturing. While this can cut costs, it can also muddy the water when something
goes wrong. If a robot misdoes a batch or an AI misreads trial outcomes, it’s often unclear who is
responsible, and that can delay fixes and put patients at risk.
Then there’s the growing world of connected medical devices, smart inhalers, implantable
delivery pumps, and wearable sensors. These tools promise valuable insights into how treatments
work in everyday life, but they also collect vast amounts of personal health data. If companies
use that information to fine-tune marketing without clear patient consent, they’re betraying
people’s trust and crossing a clear ethical line.
To handle these risks, drugmakers need to bake ethics into every digital step. That means
opening their algorithms to third-party audits, inviting patient advocates and independent experts
to advise on automated systems, and enforcing strong privacy safeguards. They should create
cross-disciplinary ethics committees with real power to pause or stop any tech rollout that might
endanger patients. And they must stay alert to rumors by monitoring social channels and swiftly
correcting misinformation.
In the end, a company’s reputation for integrity is as precious as any patent. Once rumors spread
of biased AI or botched robotics, trust is hard to rebuild. By committing transparency, patient-
centered design, and clear accountability, pharmaceutical firms can embrace tomorrow’s
technologies without sacrificing the public’s faith in modern medicine.
Case Key Issues Impact
AI Bias in Trials Underrepresentation of Ineffective drugs for
minorities marginalized groups; loss of
trust.
COVID Conspiracies "Profit-driven pandemic" Vaccine hesitancy;
narratives politicization of public health.
Fixing the System: Rules to Save Lives

Reforming the pharmaceutical system so that patient welfare comes first means putting in place
clear rules and strong incentives that reward openness and punish wrongdoing. First, penalties
for hiding data, promoting drugs off-label, or making deals that delay cheaper generics need to
far outweigh any profits companies might gain. Fines should claw back all ill-gotten revenue and
add extra damages, turning unethical shortcuts into losing bets rather than just the cost of doing
business. Next, every clinical trial should be registered in advance, with results and any safety
issues shown on public, easy-to-use dashboards. Independent auditors with real power—like
subpoena authority, should enforce these rules, and companies that don’t comply should
automatically lose their right to sell the drug and expose executives to personal liability.
We also need to stop patent tricks that stretch exclusivity beyond what’s fair. A simple fix is to
give shorter patents for small changes and longer ones only for truly innovative drugs proven in
head-to-head trials. Antitrust enforcers should review every settlement between a brand-name
company and a generic challenger and have the power to block any deal that keeps prices high.
That way, consumers won’t be stuck choosing between expensive brand drugs and nothing at
all.
Inside each company, ethics must be baked into every decision. That means setting up an
independent Ethics Oversight Board made up of patient advocates, ethicists, data experts, and
legal professionals. This board would have real authority to halt research plans, marketing
campaigns, or price hikes that put public health at risk. Like annual ESG reports, they’d publish
a yearly ethics report so investors and the public can see how well the company is doing on
honesty and social responsibility.
Whistle-blowers are often the first to spot problems, so we must protect them. Anyone who
reports data manipulation, safety lapses, or undue influence should receive legal protection, and a
financial reward tied to the harm they helped prevent. This encourages employees to speak up
long before small issues become big scandals.
Regulators like the FDA and EMA should speed up approvals for breakthrough treatments but
require robust post-market studies. Companies on accelerated pathways must carry out large
safety and effectiveness trials after approval, publish the results in open journals, and face
penalties if they miss deadlines. This keeps the focus on real-world patient outcomes, not just
fast market entry.
Making drug development a conversation, not a one-way street, means inviting patients and their
advocates into the process. Digital forums and town-hall meetings during key development
stages give those most affected a chance to share their needs, weigh risks, and raise ethical
concerns. This kind of “stakeholder engagement” ensures the industry stays connected to the
people it serves.
Finally, diseases don’t stop at borders, and neither should our efforts to keep drugmakers honest.
International agreements can standardize data sharing, joint inspections, and enforcement so
companies can’t shop for the weakest regulator. When countries work together, we build a global
system where ethical conduct is the norm, executives know they’ll be held accountable, and
revenues grow only when patient health truly improves. These commonsense rules won’t just
save lives—they’ll rebuild the public’s trust and help the industry earn its right to innovate for
years to come.

Case Key Issues Impact

Utilitarianism Redistribute profits to fund COVAX’s global vaccine
R&D sharing.
Deontology Mandate risk disclosure EU’s Clinical Trial Regulation
(public data access).
Conclusion: Health Over Profit

Putting people’s health first isn’t just a nice idea, it’s the only way for drug companies to keep
innovating and maintaining the public’s trust. When executives chase higher stock prices at the
expense of patient safety, the inevitable scandals that follow damage confidence in medicine,
spur heavy-handed regulation, and ultimately slow down the creative breakthrough’s companies
depend on. By contrast, running a business with honesty and a focus on patient needs builds
long-term value. A solid reputation for transparency and reliability, not just a string of
blockbuster drug launches, wins the support of doctors, regulators, and, most importantly,
patients.
Looking at it through a “greatest good” lens makes this even clearer. Treatments developed
under strict ethical standards tend to work better and avoid dangerous side effects, which save
lives, cut healthcare costs, and improve quality of life across the board. And from a rights-based
standpoint, treating patients as people rather than profit centers means providing clear consent
forms, sharing easy-to-read summaries of what a trial showed, both good and bad and making
promotional materials honest and balanced. That approach honors each person’s right to make
informed decisions about their own care.
We also must remember why society gives pharmaceutical companies special protections like
patents and market exclusivity: in exchange, companies agree to share full data on how well their
drugs work and what risks they carry. When firms break that agreement, by hiking prices, hiding
safety concerns, or using shady marketing tactics, they face public outrage, legal action, and
reputational damage that can dwarf any short-lived financial gain. But if they stick to the deal, by
registering trials publicly, monitoring safety after a drug hits the market, and setting fair prices,
they earn the ongoing trust that lets them keep innovating.
Turning “health over profit” from a slogan into reality means weaving ethical thinking into every
step of drug development. From the lab bench to the pharmacy shelf, R&D, compliance,
marketing, and leadership must work together. Strong whistle-blower programs and external
audits should back that up, giving employees the tools and protections they need to speak up.
When top executives champion ethical behavior and link their bonuses to real patient outcomes
instead of just sales numbers, they create a virtuous cycle: better credibility speeds up approvals,
earns doctors’ endorsements, and builds long-lasting loyalty among patients.
In a world where technology moves fast and the public watches every move, companies that put
health first will not only save lives but also secure the trust of the communities they serve. That
trust is the bedrock of modern medicine’s promise: using innovation to improve human health,
today and tomorrow.
References
[Link]
[Link]
[Link]
[Link]
[Link]
diverted-in-pharma-hospital-nexus/
[Link]
16424
[Link]
massive-ethics-violations-famed-french
[Link]
countries-to-avoid-ethics-legislation
[Link]
[Link]
[Link]
[Link]
[Link]
[Link]
[Link]
[Link]
billion-settlement-purdue-pharma-and-sackler-family-role
[Link]
literally-killing-patients/